摘要
目的对安罗替尼治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的有效性、安全性与经济性进行快速卫生技术评估。方法计算机检索知网、万方、中国生物医学文献数据库、PubMed、The Cochrane Library、Embase等中英文数据库,搜集安罗替尼治疗NSCLC的高质量临床证据、经济学评价文献,检索时限均从建库至2021年2月。由2位评价员独立筛选文献,对纳入的文献进行质量评价、数据提取、定性描述与分析。结果共纳入6篇文献,Meta分析、药物经济学研究各3篇。Meta分析显示,有效性方面,安罗替尼能显著提高晚期NSCLC患者疾病控制率,延长无进展生存期和总生存期,改善客观缓解率/有效率;安全性方面,安罗替尼发生不良反应的风险较高,但多数是可控的,常见不良反应包括高血压、手足综合征、腹泻等。药物经济学研究显示,与安慰剂相比,安罗替尼可提高质量调整生命年,但治疗成本相对较高。结论安罗替尼治疗晚期NSCLC患者有效性较好,安全性相对可控,基于目前资料尚不具有成本-效用/效果优势。
Objective To evaluate the efficacy,safety and cost-effectiveness of anlotinib in treatment of advanced non-small cell lung cancer(NSCLC)by rapid health technology assessment.Methods CNKI,Wanfang database,SinoMed,PubMed,The Cochrane Library and Embase were electronically searched to collect high-quality clinical evidence and economic evaluation literature of anlotinib in the treatment of NCSLC,from inception of the database to February 2021.Two reviewers independently screened literature,extracted data and accessed the quality of included studies.Descriptive analysis and summary were then performed.Results A total of 6 studies were included,including 3 meta-analyses and 3 pharmacoeconomic studies.In terms of effectiveness,the meta-analyses show that anlotinib can significantly improve the disease control rate and prolong progression-free survival and overall survival,improve objective response rate and effectiveness rate in patients with advanced NSCLC.In terms of safety,adverse drug reactions(ADR)of anlotinib were high,but most them were controllable.Common ADR included hypertension,hand-foot syndrome and diarrhea.Pharmacoeconomic studies have shown that compared with placebo,anlotinib could improve the quality of life-year adjustment,but the treatment cost is relatively high.Conclusion Anlotinib is effective in the treatment of patients with advanced NSCLC,and its side effects are relatively controllable.However based on current data,it may not be a costeffective option.
作者
沈姗
杨洁
刘云霞
马海明
侯宁
Shan SHEN;Jie YANG;Yun-Xia LIU;Hai-Ming MA;Ning HOU(Department of Pharmacy,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China;Department of Pharmacy,Shandong Provincial Hospital(group)Ludong Hospital,Yantai 246000,Shandong Province,China;Pharmaceutical College,Shandong First Medical University,Jinan 250021,China;Guangrao County People's Hospital,Dongying 257300,Shandong Province,China)
出处
《医学新知》
CAS
2021年第5期350-356,共7页
New Medicine
基金
中华国际医学交流基金会资助项目(Z-2018-32-180052)。
关键词
安罗替尼
晚期非小细胞肺癌
快速卫生技术评估
Anlotinib
Advanced non-small cell lung cancer
Rapid health technology assessment
